Demographic variables, disease related and therapy variables, damage, bone mineral density, and fractures
| All patients | RAPIT | Remission | |
|---|---|---|---|
| (n = 373) | (n = 297) | (n = 76) | |
| Mean (SD) for continuous variables with normal distribution. Median (IQR) for continuous variables with non-normal distribution. ACR, American College of Rheumatology; BMD, bone mineral density; BMI, body mass index; DAS, disease activity score; DMARD, disease modifying anti rheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; HRT, hormone replacement therapy; anti-osteoporotic drugs, hormone replacement therapy, bisphosphonates, calcium, and/or vitamin D supplementation; VAS, visual analogue scale. | |||
| Demographic variables | |||
| Age (years) | 53.8 (11.9) | 52.0 (11.1) | 60.9 (12.3) |
| Sex (women/men) (%) | 77/23 | 79/21 | 68/32 |
| BMI (kg/m2) | 26.4 (4.8) | 26.7 (5.0) | 25.3 (3.5) |
| Menopause (%) | 63.5 | 60.7 | 75.0 |
| Menopause age (years) | 46.8 (5.3) | 46.8 (5.0) | 46.9 (6.6) |
| Current smoker (%) | 24.6 | 23.8 | 27.6 |
| Disease variables | |||
| Disease duration (years) | 7.0 (4.0 to 13.0) | 6.0 (3.0 to 12.0) | 9.0 (6.0 to 18.0) |
| Rheumatoid factor positive (%) | 66 | 72 | 43 |
| Investigator’s global assessment (VAS 0–100 mm) | 20.0 (7.0 to 34.8) | 24.0 (10.0 to 37.5) | 12.0 (3.0 to 19.0) |
| Pain (VAS 0–100 mm) | 30.0 (10.0 to 54.0) | 32.0 (13.0 to 57.0) | 14.0 (4.8 to 37.0) |
| Disease activity (VAS 0–100 mm) | 27.0 (10.0 to 51.0) | 32.0 (13.0 to 52.5) | 16.0 (4.0 to 29.5) |
| HAQ (range 0–3) | 0.6 (0.3 to 1.0) | 0.6 (0.3 to 1.0) | 0.5 (0.0 to 1.1) |
| Ritchie score | 2 (2 to 13) | 8 (4 to 14) | 2 (0 to 5) |
| 44 swollen joint count | 10 (5 to 16) | 12 (6 to 18) | 4 (2 to 8) |
| ESR (mm/1st hour) | 15.0 (8.0 to 27.0) | 17.0 (8.0 to 29.0) | 11.0 (5.0 to 22.0) |
| DAS | 3.2 (1.4) | 3.5 (1.3) | 2.0 (1.1) |
| ACR functional class (I/II/III) (%) | 31.4/40.2/28.4 | 18.2/48.5/33.3 | 82.9/7.9/9.2 |
| Therapy variables | |||
| Corticosteroids (%) | |||
| Never user | 82.8 | 84.2 | 71.1 |
| Previous user | 9.3 | 4.7 | 26.3 |
| Current user | 7.9 | 9.1 | 2.6 |
| Ever user of DMARDs (%) | 95.6 | 96.2 | 93.4 |
| Current user of HRT (%) | 3.8 | 2.2 | 9.6 |
| Current user of bisphophonates (%) | 3.0 | 2.4 | 5.3 |
| Current user of anti-osteoporotic drugs (%) | 12.5 | 9.5 | 22.4 |
| Damage variable | |||
| Larsen score hands and feet (0–200) | 27.0 (5.0 to 61.0) | 31.0 (5.5 to 62.5) | 15.0 (2.0 to 51.0) |
| BMD variables | |||
| BMD femoral neck (g/cm2) | 0.78 (0.13) | 0.78 (0.13) | 0.80 (0.14) |
| BMD spine L1–4 (g/cm2) | 0.99 (0.16) | 1.00 (0.16) | 0.98 (0.16) |
| Z score femoral neck | −0.06 (1.08) | 0.09 (1.04) | −0.64 (1.06) |
| Z score spine L1–4 | 0.59 (1.88) | 1.01 (1.79) | −1.07 (1.23) |
| T score femoral neck | −0.76 (1.15) | −0.78 (1.17) | −0.67 (1.04) |
| T score spine L1–4 | −0.87 (1.40) | −0.82 (1.42) | −1.07 (1.34) |
| Fractures | |||
| Fracture 1st degree relative (%) | 15.3 | 15.9 | 13.2 |
| Fracture patient>age 25 (%) | 18.2 | 16.7 | 23.7 |